

Lysosomal Storage Disease

How to Cite this Article: Ghofrani M. Lysosomal Storage Disease. Iran J Child Neurol Autumn 2012; 6:4 (suppl. 1):1-2.

Mohammad GHOFRANI MD^{1,2}

Lysosomes are cytoplasmic organelles containing hydrolytic enzymes that degrade the macromolecules proteins of cellular catabolism. The causes of lysosomal enzyme disorder stem from

1. Impaired enzyme synthesis
2. Abnormal enzyme targeting
3. Defect of structure of Accessory factor which is needed for enzymes function. Clinical manifestations depend on the organ(s) involved.

Seizure disorder, mental handicap and regression are the characteristics of many lysosomal enzyme storage diseases. The lysosomal storage disease, as first described by Hers are characterized by an accumulation of undergraded macromolecules within lysosomes. These disorders are clinically heterogenous groups of inborn errors by about 50 different clinical entities. Nature of the incompletely degraded macromolecules that accumulate in various tissues include:

The glycogen storage diseases

The mucopolysaccharidosis

The mucopolidosis

The glycoproteinosis

The sphingolipidosis

The acid lipase deficiency diseases

It is said the combined prevalence of all lysosomal storage disease is 1 in 6600 to 1 in 7700 live birth (1).

The disease entities result from various single gene mutation with each of the enzyme defect is induced by one of the several different abnormalities. Mutation or deletions that produce immunologically responsive or unresponsive enzyme protein. The defect can impair glycosylation of the enzyme protein or cause a failure to generate recognition markers that permits the enzyme to attach itself to the lysosomal membrane. The majority of genes that encode lysosomal various lysosomal storage disease subtypes is manifested by multi systemic involvement. Disease manifestation may be evident prenatally or at any time from birth to adulthood on the therapeutic front several modalities of treatment have been suggested Enzyme replacement therapy, enzyme enhancement therapy, substrate reduction therapy and gene therapy are the

1. Professor of Pediatric Neurology,
Pediatric Neurology Research
Center, Shahid beheshti University of
Medical Sciences, Tehran, Iran
2. Professor of Pediatric Neurology,
Department of Pediatric Neurology,
Mofid Children Hospital, Shahid
Beheshti University of Medical
Sciences, Tehran, Iran

Corresponding Author:
Ghofrani M. MD
Mofid Children Hospital,
Shariati Ave, Tehran, Iran
Tel: +98 21 22909559
Email: ijcn.journal@gmail.com

different approaches which at present, are being tried. Treatment of the secondary disabilities like seizure disorder, sensory deficit, behavioral problem, and sleep-wake cycle disorder has positive impact on the patients quality of life and help address some of parental anxieties. Genetic counseling of affected individuals and their relatives is also important component of care of the patient and family.

Keywords:Lysosome; Enzyme; Gene therapy; Child

References:

1. Meikle PJ, Hopwood JJ, Clange AE, et al. prevalence of lysosomal storage disorders. *Am Med Assoc* 1999; 281: 249-254.
2. Hers Gh. Inborn lysosomal diseases. *Gastroenterology* 1963; 58:605-633.